


(PQ 83)

INTERIM FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2021.



Registered office: Level 04, Access Towers, No. 278, Union Place,

Colombo 2, Sri Lanka.

Tel: 94 11 4760000, / Fax: 94 4760076

www.vidullanka.com

STATEMENT OF FINANCIAL POSITION

		oup	Company		
As at	31.03.2021	31.03.2020	31.03.2021	31.03.2020	
	(Unaudited*)	(Audited)	(Unaudited*)	(Audited)	
	Rs.	Rs.	Rs.	Rs.	
ASSETS					
Non-Current Assets					
Property , Plant & Equipment	5,687,621,873	4,932,208,960	445,214,980	446,284,304	
Mature bearer biological assets	45,705,335	25,607,709	-	-	
Right of Use asset	169,383,284	169,148,138	16,753,018	13,134,049	
Investments in Subsidiaries	-	-	1,318,896,133	1,318,896,133	
Investments in Joint Ventures & Associates	641,065,048	572,994,834	414,291,550	414,291,550	
Other Project Investments	70,772,608	91,991,105	70,772,608	91,991,105	
Goodwill	275,691,621	277,174,512	-	-	
Deferred Tax Asset	611,652	542,659	-	-	
	6,890,851,421	6,069,667,917	2,265,928,290	2,284,597,141	
Inventories	49,129,341	31,865,565	6,490,051	6,058,913	
Trade and Other Receivables	976,585,524	882,888,947	468,388,149	509,376,557	
Other Financial Assets	31,841,500	31,841,500	31,841,500	31,841,500	
Cash and Bank Balances	414,816,493	366,223,883	106,305,616	7,637,282	
	1,472,372,858	1,312,819,895	613,025,317	554,914,252	
Total Assets	8,363,224,279	7,382,487,812	2,878,953,607	2,839,511,393	
EQUITY AND LIABILITIES					
Capital and Reserves					
Stated Capital	1,469,839,867	1,417,908,484	1,469,839,867	1,417,908,484	
Retaining Earnings	1,835,949,810	1,338,790,365	31,937,675	662,268	
Other components of equity	271,475,387	188,042,668	-	-	
Equity attributable to Equity Holders of the Parent	3,577,265,064	2,944,741,517	1,501,777,541	1,418,570,752	
Non Controlling Interest	71,249,233	56,055,377	-	-	
Total Equity	3,648,514,297	3,000,796,894	1,501,777,541	1,418,570,752	
Non- Current Liabilities					
Loans and Borrowings	2,722,414,377	2,350,231,672	587,030,336	550,000,000	
Defined Benefit Liability	39,337,270	33,355,135	32,375,224	28,371,220	
Deferred Tax Liability	341,942,794	283,192,233	11,685,502	10,264,733	
Lease Liability	84,377,469	87,540,780	5,873,062	8,267,600	
	3,188,071,910	2,754,319,820	636,964,125	596,903,553	
Current Liabilities					
Loans and Borrowings	1,112,792,220	1,047,593,612	610,529,091	538,118,673	
Lease Liability	28,945,698	10,809,220	6,005,090	5,591,060	
Trade and Other Payables	357,942,723	479,111,776	119,536,806	280,327,355	
Income Tax Liability	26,957,431	89,856,490	4,140,954	· · · · · · · · · · · · · · · · · · ·	
•	1,526,638,072	1,627,371,098	740,211,941	824,037,088	
Total Equity and Liabilities	8,363,224,279	7,382,487,812	2,878,953,607	2,839,511,393	
Net Asset Value Per Share (Rs)	4.22	3.51	1.77	1.69	
No of Issued Shares	848,458,689	837,785,465	848,458,689	837,785,465	

^{*} The amounts are provisional and subject to audit

These Financial Statements are in compliance with the requirement of the Companies Act No. 07 of 2007

(Signed)
Mafaz Ansar
Finance Controller

 $The \ Board \ of \ Directors \ is \ responsible \ for \ the \ Preparation \ and \ presentation \ of \ these \ financial \ statements.$

(Signed) (Signed)

Riyaz M.Sangani Rizvi Zaheed
CEO Director

Colombo 31st May 2021

STATEMENT OF COMPREHENSIVE INCOME

	Group					
		Ended 31st March	1	Twelve Mon	ths Ended 31st M	arch
	2021	2020	Variance	2021	2020	Variance
	(Unaudited*) Rs.	(Unaudited*) Rs.	%	(Unaudited*) Rs.	(Unaudited*) Rs.	%
	No.	ns.		ns.	ns.	
Revenue	427,598,499	356,334,414	20	1,797,134,148	1,440,380,462	25
Cost of Sales	(158,887,577)	(112,951,846)	(41)	(594,136,386)	(377,897,714)	(57)
Gross Profit	268,710,923	243,382,568	10	1,202,997,762	1,062,482,748	13
Other Income and Gain/(Losses)	16,736,757	76,505,732	(78)	119,940,432	77,626,039	55
Administrative Expenses	(78,598,520)	(89,185,679)	12	(301,342,693)	(270,517,125)	(11)
Finance Cost	(77,541,731)	(89,391,221)	13	(311,331,669)	(320,155,540)	3
Finance Income	(3,260,423)	1,359,007	(340)	1,158,889	2,908,304	(60)
Investment Share in the Joint Ventures & Associate	22,245,972	(16,984,298)	231	108,438,586	29,754,121	264
Profit Before Tax	148,292,977	125,686,108	18	819,861,307	582,098,547	41
Income Tax Expense	(51,213,247)	(42,794,350)	(20)	(218,828,018)	(220,436,714)	1
Profit for the period	97,079,730	82,891,758	17	601,033,289	361,661,833	66
Other Comprehensive Income (OCI)						
Net Actuarial Gain/(Loss) on Defined Benefit Plan	63,889	295,246	78	(424,510)	(138,088)	(207)
Income Tax on Other Comprehensive Income	31,445	(56,610)	156	118,443	14,298	(728)
Net Actuarial Gain/(Loss) on Defined Benefit Plan of Investment share	-	619,041	(100)	378	621,403	(100)
Exchange Differences on Translation of Foreign Operations	120,029,531	45,636,014	163	86,807,956	86,247,693	1
Other Comprehensive Income for the Year, Net of Tax	120,124,865	46,493,691	(158)	86,502,267	86,745,306	(0)
Total Comprehensive Income for the Year, Net of Tax	217,204,595	129,385,449	68	687,535,556	448,407,139	53
Profit attributable to :						
Equity Holders of the Parent	93,615,499	73,962,348	27	581,660,313	344,143,760	69
Non-Controlling Interest	3,464,232	8,929,410	(61)	19,372,975	17,518,073	11
Total Profit for the period	97,079,730	82,891,758	17	601,033,289	361,661,833	66
Total Comprehensive Income attributable to :						
Equity Holders of the Parent	210,364,698	120,455,165	75	664,787,343	430,888,495	54
Non-Controlling Interest	6,839,898	8,930,284	(23)	22,748,213	17,518,644	30
Total Comprehensive Income for the Year	217,204,595	129,385,449	68	687,535,556	448,407,139	53
Total Complehensive income for the real	217,204,335	125,305,445	UO	007,333,330	440,407,133	33
Earnings Per Share	0.11	0.09		0.69	0.41	
Diluted Earnings Per Share	0.11	0.09		0.69	0.41	
Weighted Average No of Shares	840,551,992	839,385,707		840,551,992	839,385,707	

STATEMENT OF COMPREHENSIVE INCOME

				pany		
		Ended 31st Marc	h		ths Ended 31st N	/larch
	2021 (Unaudited*) Rs.	2020 (Unaudited*) Rs.	Variance %	2021 (Unaudited*) Rs.	2020 (Unaudited*) Rs.	Variance %
				<u> </u>		
Revenue	54,586,297	47,351,375	15	310,727,026	288,524,941	8
Cost of Sales	(14,190,239)	(12,830,839)	(11)	(51,603,120)	(48,726,744)	(6)
Gross Profit	40,396,058	34,520,536	17	259,123,906	239,798,197	8
Other Income and Gain/(Losses)	95,271,655	156,096,976	(39)	236,170,781	258,899,857	(9)
Administrative Expenses	(65,140,258)	(49,697,985)	(31)	(228,691,187)	(197,802,087)	(16)
Finance Cost	(34,374,660)	(38,370,193)	10	(146,400,125)	(129,096,357)	(13)
Finance Income	(3,266,613)	1,350,257	(342)	1,133,501	2,671,922	(58)
Profit Before Tax	32,886,181	103,899,591	(68)	121,336,876	174,471,532	(30)
Income Tax Expense	(5,561,723)	(10,193,213)	45	(5,561,723)	(10,264,733)	46
Profit for the period	27,324,458	93,706,378	(71)	115,775,153	164,206,799	(29)
Other Comprehensive Income						
Net Actuarial Gain/(Loss) on Defined Benefit Plan	(105,753)	43,923	341	(423,010)	(211,505)	(100)
Income Tax on Other Comprehensive Income	29,611	(41,909)	171	118,443	29,611	(300)
Other Comprehensive Income for the Year, Net of Tax	(76,142)	2,013	3882	(304,567)	(181,894)	(67)
Total Comprehensive Income for the Year, Net of Tax	27,248,316	93,708,391	(71)	115,470,585	164,024,905	(30)
Profit attributable to :						
	27 224 450	02 706 270	(74)	145 775 452	164 206 700	(20)
Equity Holders of the Parent	27,324,458	93,706,378	(71)	115,775,153	164,206,799	(29)
Total Profit for the period	27,324,458	93,706,378	(71)	115,775,153	164,206,799	(29)
Total Comprehensive Income attributable to :						
Equity Holders of the Parent	27,248,316	93,708,391	(71)	115,470,585	164,024,905	(30)
Total Comprehensive Income for the Year	27,248,316	93,708,391	(71)	115,470,585	164,024,905	(30)
Earnings Per Share	0.03	0.11		0.14	0.20	
Diluted Earnings Per Share	0.03	0.11		0.14	0.20	
Weighted Average No of Shares	840,551,992	839,385,707		840,551,992	839,385,707	

^{*} The amounts are provisional and subject to audit

^{**} The variance indicates the impact on the profitability

STATEMENT OF CHANGES IN EQUITY

GROUP	Stated Capital	Retained Earnings	Foreign Currency Translation Reserve	Non-Controlling Interest	Total
	Rs	Rs	Rs	Rs	Rs
Balance as at 1st April 2019	1,417,908,484	1,192,078,259	101,794,975	41,587,769	2,753,369,487
Profit for the Period		344,143,760	-	17,518,073	361,661,833
Other Comprehensive Income		497,043	86,247,693	570	86,745,306
Total Comprehensive Income for the Year	-	344,640,803	86,247,693	17,518,643	448,407,139
Prior Year Adjustment		(9,426,967)			(9,426,967)
Dividend Paid		(104,723,183)	-	(3,051,035)	(107,774,218)
Dividend Payable as at End of the Year		(83,778,547)			(83,778,547)
Balance as at 31st March 2020	1,417,908,484	1,338,790,365	188,042,668	56,055,377	3,000,796,894
Balance as at 1st April 2020	1,417,908,484	1,338,790,365	188,042,668	56,055,377	3,000,796,894
Profit for the period	-	581,660,313	-	19,372,975	601,033,289
Other Comprehensive Income	-	(305,689)	83,432,719	3,375,237	86,502,267
Total Comprehensive Income for the Year	-	581,354,624	83,432,719	22,748,213	687,535,556
Subscription to ESOS	51,931,383				51,931,383
Dividend Paid	-	(84,195,179)	-	(7,554,357)	(91,749,536)
Balance as at 31st March 2021	1,469,839,867	1,835,949,810	271,475,387	71,249,233	3,648,514,297

COMPANY	Stated Capital	Retained Earnings	Total
	Rs	Rs	Rs
Balance as at 1st April 2019	1,417,908,484	34,566,059	1,452,474,543
Profit for the Period	-	70,500,421	70,500,421
Other Comprehensive Income	-	(183,908)	(183,908)
Total Comprehensive Income for the Year	-	70,316,513	70,316,513
Dividend Paid	-	(104,723,183)	(104,723,183)
Balance as at 31st March 2020	1,417,908,484	159,389	1,418,067,873
Balance as at 1st April 2020	1,417,908,484	662,268	1,418,570,752
Profit for the period	-	115,775,153	115,775,153
Other Comprehensive Income	-	(304,567)	(304,567)
Total Comprehensive Income for the Year	-	115,470,585	115,470,585
Dividend Paid	-	(84,195,179)	(84,195,179)
Subscription to ESOS	51,931,383	-	51,931,383
Balance as at 31st March 2021	1,469,839,867	31,937,675	1,501,777,541

STATEMENT OF CASH FLOWS

As at Cash Flows From/(Used in) Operating Activities Profit from Ordinary Activities Before Tax Adjustments for Depreciation Property, Plant and Equipment Amortization of Right to Use Assets Expenses on Defined Benefit Plan Dividend Income Provision for Impairment / Written Off - New Projects Impairment / Written -Off - Biological asset Unrealized Exchange (Gain)/Loss Share of Profits from Joint Ventures Finance Income Finance Cost Amortization of Goodwill Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes (Increase)/Decrease in Inventories (Increase)/Decrease in Trade & Other Payables Transfer of expenses from Operations Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid Income Tax Paid Net Cash From Operating Activities Acquisition of Right to Use Asset (21,925,8 Acquisition of Right to Use Asset (19,706,0 Proceeds from sale of Property, Plant and Equipment Investment in New Projects (19,218,4 Investment in New Projects (19,218,4 Investment in New Projects (19,218,4 Investment in New Projects (19,706,0 Investment in New Projects (19,218,4	Rs. 24 150,165,822 25 14,550,695 36 (943,619) 31 6,218,451 30 2,468,182 38 300 - 36 (29,754,121) 33 (3,078,793) 33 320,155,540 34 (886,057) 35 1,056,520,248 35 (11,223,358) 35 (353,181,544)	3,699,438 (217,213,930) 12,000,000 - - (1,133,501) 146,400,125 - 79,225,741 (431,138)	5,294,396 (257,980,250) 580,309 - - - (2,671,922) 129,096,357 - 74,738,305
Profit from Ordinary Activities Before Tax Adjustments for Depreciation Property, Plant and Equipment Amortization of Right to Use Assets 16,437,3 (Profit) / Loss on Disposal of Property, Plant and Equipment Expenses on Defined Benefit Plan Dividend Income Provision for Impairment / Written Off - New Projects Impairment / Written Off - Biological asset Unrealized Exchange (Gain)/Loss Hot (Gain) / Loss on Translation of Foreign Currency Share of Profits from Joint Ventures Finance Income Finance Cost Amortization of Goodwill Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes (Increase)/Decrease in Inventories (Increase)/Decrease in Inventories (Increase)/Decrease in Inventories Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations Net Cash From (Used In) Investing Activities Acquisition of Ropoerty, Plant and Equipment Investment in Mature Biological Assets Proceeds from sale of Property, Plant and Equipment Investment in New Projects Polation Investment in New Projects Polation Investment in New Projects Polation Pola	24 150,165,822 75 14,550,695 76 (943,619) 76 (943,619) 77 (943,619) 78 (943,619) 79 (943,619) 70 2,468,182 70 - 70 14,091,529 70 (3,078,793) 70 (3,078,793) 70 (886,057) 70 (11,223,358) 70 (11,223,358) 70 (353,181,544)	21,233,759 6,087,076 (13,184,102) 3,699,438 (217,213,930) 12,000,000 (1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	21,659,258 5,232,243 (943,619) 5,294,396 (257,980,250) 580,309 (2,671,922) 129,096,357 - 74,738,305
Adjustments for Depreciation Property, Plant and Equipment 194,273,8 Amortization of Right to Use Assets (16,437,3 (Profit) / Loss on Disposal of Property, Plant and Equipment 13,086,8 Expenses on Defined Benefit Plan 5,390,5 Dividend Income Provision for Impairment / Written Off - New Projects 12,000,0 Impairment / Written -Off - Biological asset 1,828,1 Unrealized Exchange (Gain)/Loss Net (Gain) / Loss on Translation of Foreign Currency 14,708,1 Share of Profits from Joint Ventures (108,438,5 Finance Income (1,124,2 Finance Cost 310,867,3 Amortization of Goodwill 1,482,8 Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes (Increase)/Decrease in Inventories (Increase)/Decrease in Trade & Other Receivables Increase/(Decrease) in Trade & Other Payables Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (129,499,4 Investment in Mature Biological Assets Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Investment in New Projects 9,218,4	24 150,165,822 75 14,550,695 76 (943,619) 76 (943,619) 77 (943,619) 78 (943,619) 79 (943,619) 70 2,468,182 70 - 70 14,091,529 70 (3,078,793) 70 (3,078,793) 70 (886,057) 70 (11,223,358) 70 (11,223,358) 70 (353,181,544)	21,233,759 6,087,076 (13,184,102) 3,699,438 (217,213,930) 12,000,000 (1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	21,659,258 5,232,243 (943,619) 5,294,396 (257,980,250) 580,309 (2,671,922) 129,096,357 - 74,738,305
Depreciation Property, Plant and Equipment Amortization of Right to Use Assets (Profit) / Loss on Disposal of Property, Plant and Equipment Expenses on Defined Benefit Plan Dividend Income Provision for Impairment / Written Off - New Projects Inception of Impairment / Written Off - New Projects Inception of Impairment / Written Off - New Projects Inception of Impairment / Written Off - New Projects Inception of Impairment / Written Off - New Projects Inception of Impairment / Written Off - New Projects Inception of Impairment / Written Off - New Projects Inception of Impairment / Written Off - New Projects Inception of Inception of Inception of Inception Currency Inception of Inception of Inception Currency Inception of Inception Off Inception Off Inception Currency Inception Off Inception I	75 14,550,695 16) (943,619) 11 6,218,451 10 2,468,182 10 - 10 14,091,529 10 (29,754,121) 10 (3,078,793) 10 1,434,074 (886,057) 1,056,520,248 15) (11,223,358) 15 (353,181,544)	6,087,076 (13,184,102) 3,699,438 (217,213,930) 12,000,000 (1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	5,232,243 (943,619) 5,294,396 (257,980,250) 580,309 - - (2,671,922) 129,096,357 - 74,738,305
Amortization of Right to Use Assets (Profit) / Loss on Disposal of Property, Plant and Equipment (13,086,8 Expenses on Defined Benefit Plan 5,390,5 Dividend Income Provision for Impairment / Written Off - New Projects 12,000,0 Impairment / Written -Off - Biological asset 1,828,1 Unrealized Exchange (Gain)/Loss 3,677,1 Net (Gain) / Loss on Translation of Foreign Currency 14,708,1 Share of Profits from Joint Ventures (108,438,5 Finance Income (1,124,2 Finance Cost 310,867,3 Amortization of Goodwill 1,482,8 Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes (Increase)/Decrease in Inventories (Increase)/Decrease in Inventories (Increase)/Decrease in Trade & Other Receivables Increase/(Decrease) in Trade & Other Payables Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid Defined Benefit Plan Costs Paid Income Tax Paid (239,022,5 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment Investment in Mature Biological Assets Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment Investment in New Projects 9,218,4	75 14,550,695 16) (943,619) 11 6,218,451 10 2,468,182 10 - 10 14,091,529 10 (29,754,121) 10 (3,078,793) 10 1,434,074 (886,057) 1,056,520,248 15) (11,223,358) 15 (353,181,544)	6,087,076 (13,184,102) 3,699,438 (217,213,930) 12,000,000 (1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	5,232,243 (943,619) 5,294,396 (257,980,250) 580,309 - - - (2,671,922) 129,096,357 - 74,738,305
(Profit) / Loss on Disposal of Property, Plant and Equipment Expenses on Defined Benefit Plan 5,390,5 Dividend Income Provision for Impairment / Written Off - New Projects 12,000,0 Impairment / Written - Off - Biological asset 1,828,1 Unrealized Exchange (Gain)/Loss 3,677,1 Net (Gain) / Loss on Translation of Foreign Currency 14,708,1 Share of Profits from Joint Ventures (108,438,5 Finance Income (1,124,2 Finance Cost 310,867,3 Amortization of Goodwill Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes (Increase)/Decrease in Inventories (Increase)/Decrease in Trade & Other Receivables Increase/(Decrease) in Trade & Other Payables Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid Defined Benefit Plan Costs Paid Income Tax Paid (239,022,5 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment Investment in Mature Biological Assets Acquisition of Right to Use Asset Proceeds from sale of Property, Plant and Equipment Investment in New Projects 9,218,4	16) (943,619) 11 6,218,451 10 2,468,182 18 10 - 10 14,091,529 136) (29,754,121) 133) (3,078,793) 134,074 (886,057) 1,056,520,248 15) (11,223,358) 15 (353,181,544)	(13,184,102) 3,699,438 (217,213,930) 12,000,000 (1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	(943,619) 5,294,396 (257,980,250) 580,309 (2,671,922) 129,096,357 - 74,738,305
Expenses on Defined Benefit Plan Dividend Income Provision for Impairment / Written Off - New Projects Inpairment / Written - Off - Biological asset Unrealized Exchange (Gain)/Loss 3,677,1 Net (Gain) / Loss on Translation of Foreign Currency 14,708,1 Share of Profits from Joint Ventures Finance Income (1,124,2 Finance Cost 310,867,3 Amortization of Goodwill Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes (Increase)/Decrease in Inventories (Increase)/Decrease in Trade & Other Receivables Increase/(Decrease) in Trade & Other Payables Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid Defined Benefit Plan Costs Paid Income Tax Paid (239,022,5 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment Investment in Mature Biological Assets Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment Investment in New Projects 9,218,4	6,218,451 6,218,451 7,2468,182 7,360 7,4091,529 7,360 7,4091,529 7,360 7,378,793 7,378,793 7,434,074 7,434,074 7,434,074 7,434,074 7,434,074 7,434,074 8,86,057) 7,056,520,248 7,11,223,358) 7,11,223,358) 7,11,223,358) 7,11,223,358)	3,699,438 (217,213,930) 12,000,000 (1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	5,294,396 (257,980,250) 580,309 - - - (2,671,922) 129,096,357 - 74,738,305
Dividend Income Provision for Impairment / Written Off - New Projects 12,000,0 Impairment / Written - Off - Biological asset 1,828,1 Unrealized Exchange (Gain)/Loss 3,677,1 Net (Gain) / Loss on Translation of Foreign Currency 14,708,1 Share of Profits from Joint Ventures (108,438,5 Finance Income (1,124,2 Finance Cost 310,867,3 Amortization of Goodwill 1,482,8 Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes (Increase)/Decrease in Inventories (Increase)/Decrease in Trade & Other Receivables Increase/(Decrease) in Trade & Other Payables Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid Defined Benefit Plan Costs Paid Income Tax Paid (239,022,5 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment Investment in Mature Biological Assets Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment Investment in New Projects 9,218,4	2,468,182 98 90 57 14,091,529 36) (29,754,121) 53) (3,078,793) 53 320,155,540 90 1,434,074 (886,057) 60 1,056,520,248 15) (11,223,358) 05 (353,181,544)	(217,213,930) 12,000,000 (1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	(257,980,250) 580,309 - - - (2,671,922) 129,096,357 - 74,738,305
Provision for Impairment / Written Off - New Projects Ingairment / Written - Off - Biological asset Ingairment / Loss on Translation of Foreign Currency Interpretation of Profits from Joint Ventures Interpretation of Profits from Joint Ventures Interpretation of Profits from Joint Ventures Interpretation of Goodwill Interpretation of Interpretation Interpretation Interpretation Interpretation Interpretation Interpretation Inter	98 900 - 57 14,091,529 36) (29,754,121) 33) (3,078,793) 33 320,155,540 90 1,434,074 (886,057) 60 1,056,520,248 35) (11,223,358) 95 (353,181,544)	12,000,000 (1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	580,309 (2,671,922) 129,096,357 - 74,738,305
Impairment / Written -Off - Biological asset 1,828,1 Unrealized Exchange (Gain)/Loss 3,677,1 Net (Gain) / Loss on Translation of Foreign Currency 14,708,1 Share of Profits from Joint Ventures (108,438,5 Finance Income (1,124,2 Finance Cost 310,867,3 Amortization of Goodwill 1,482,8 Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes 1,257,877,0 (Increase)/Decrease in Inventories (15,792,4 (Increase)/Decrease in Trade & Other Receivables 140,841,6 Increase/(Decrease) in Trade & Other Payables (305,271,6 Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	98 900 - 57 14,091,529 36) (29,754,121) 33) (3,078,793) 33 320,155,540 90 1,434,074 (886,057) 60 1,056,520,248 35) (11,223,358) 95 (353,181,544)	- (1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	- - - (2,671,922) 129,096,357 - 74,738,305
Unrealized Exchange (Gain)/Loss 3,677,1 Net (Gain) / Loss on Translation of Foreign Currency 14,708,1 Share of Profits from Joint Ventures (108,438,5 Finance Income (1,124,2 Finance Cost 310,867,3 Amortization of Goodwill 1,482,8 Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes 1,257,877,0 (Increase)/Decrease in Inventories (15,792,4 (Increase)/Decrease in Trade & Other Receivables 140,841,6 Increase)/Decrease in Trade & Other Payables (305,271,6 Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5) Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	00 - 14,091,529 16) (29,754,121) 16) (3,078,793) 17) (3,078,793) 17) (3,078,793) 17) (3,078,793) 17) (3,078,793) 17) (4,078,793) 17) (4,078,793) 17) (4,078,793) 18) (11,223,358) 18) (11,223,358) 19) (353,181,544)	(1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	129,096,357 - 74,738,305
Share of Profits from Joint Ventures Finance Income (1,124,2 Finance Cost 310,867,3 Amortization of Goodwill 1,482,8 Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes (15,792,4 (Increase)/Decrease in Inventories (15,792,4 (Increase)/Decrease in Trade & Other Receivables Increase/(Decrease) in Trade & Other Payables (305,271,6 Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5 Net Cash From Operating Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	36) (29,754,121) 33) (3,078,793) 33 320,155,540 30 1,434,074 (886,057) 30 1,056,520,248 31 (11,223,358) 31 (353,181,544)	(1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	129,096,357 - 74,738,305
Finance Income (1,124,2 Finance Cost 310,867,3 Amortization of Goodwill 1,482,8 Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes 1,257,877,0 (Increase)/Decrease in Inventories (15,792,4 (Increase)/Decrease in Trade & Other Receivables 140,841,6 Increase/(Decrease) in Trade & Other Payables (305,271,6 Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5 Net Cash From Operating Activities 532,702,0 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	(3,078,793) (3,078,793) (3,078,793) (3,078,793) (4,434,074) (886,057) (886,057) (1,056,520,248) (11,223,358) (353,181,544)	(1,133,501) 146,400,125 - 79,225,741 (431,138) 40,988,408	129,096,357 - 74,738,305
Finance Cost 310,867,3 Amortization of Goodwill 1,482,8 Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes 1,257,877,0 (Increase)/Decrease in Inventories (15,792,4 (Increase)/Decrease in Trade & Other Receivables 140,841,6 Increase/(Decrease) in Trade & Other Payables (305,271,6 Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5) Net Cash From Operating Activities 532,702,0 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	33 320,155,540 90 1,434,074 (886,057) 1,056,520,248 45) (11,223,358) 95 (353,181,544)	146,400,125 - 79,225,741 (431,138) 40,988,408	129,096,357 - 74,738,305
Amortization of Goodwill Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes 1,257,877,0 (Increase)/Decrease in Inventories (Increase)/Decrease in Trade & Other Receivables Increase/(Decrease) in Trade & Other Payables Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5) Net Cash From Operating Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	1,434,074 (886,057) (80 1,056,520,248 (11,223,358) (353,181,544)	- 79,225,741 (431,138) 40,988,408	74,738,305
Stock Written (Back) / Off Operating Profit/(Loss) Before Working Capital Changes 1,257,877,0 (Increase)/Decrease in Inventories (Increase)/Decrease in Trade & Other Receivables Increase/(Decrease) in Trade & Other Payables Increase/(Decrease) in Trade & Other Payables Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5 Net Cash From Operating Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	(886,057) 1,056,520,248 15) (11,223,358) 15) (353,181,544)	79,225,741 (431,138) 40,988,408	
Operating Profit/(Loss) Before Working Capital Changes 1,257,877,0 (Increase)/Decrease in Inventories (Increase)/Decrease in Trade & Other Receivables Increase/(Decrease) in Trade & Other Payables (305,271,6 Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5) Net Cash From Operating Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	1,056,520,248 15) (11,223,358) 05 (353,181,544)	79,225,741 (431,138) 40,988,408	
(Increase)/Decrease in Inventories (15,792,4 (Increase)/Decrease in Trade & Other Receivables 140,841,6 Increase/(Decrease) in Trade & Other Payables (305,271,6 Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5 Net Cash From Operating Activities 532,702,0 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	(11,223,358) (353,181,544)	(431,138) 40,988,408	
(Increase)/Decrease in Trade & Other Receivables 140,841,6 Increase/(Decrease) in Trade & Other Payables (305,271,6 Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5) Net Cash From Operating Activities 532,702,0 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	05 (353,181,544)	40,988,408	(1.064.000)
Increase/(Decrease) in Trade & Other Payables Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5 Net Cash From Operating Activities Acquisition of Property, Plant and Equipment Investment in Mature Biological Assets Acquisition of Right to Use Asset Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4			(1,064,900)
Transfer of expenses from other project investment to relevant project companies Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5 Net Cash From Operating Activities Salance Cost Paid (119,4 Income Tax Paid (239,022,5) Net Cash From Operating Activities Acquisition of Property, Plant and Equipment Investment in Mature Biological Assets Acquisition of Right to Use Asset Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	207,038,923	(160.790.549)	(82,277,379)
Cash Generated from Operations 1,077,654,5 Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid Income Tax Paid (239,022,5 Net Cash From Operating Activities Acquisition of Property, Plant and Equipment Investment in Mature Biological Assets Acquisition of Right to Use Asset Proceeds from sale of Property, Plant and Equipment Investment in New Projects 9,218,4		(200): 50,5 .57	46,747,653
Finance Cost Paid (305,810,5 Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5 Net Cash From Operating Activities 532,702,0 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	-		-
Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5 Income Tax Paid Incom	899,154,269	(41,007,539)	38,143,678
Defined Benefit Plan Costs Paid (119,4 Income Tax Paid (239,022,5 Net Cash From Operating Activities 532,702,0 Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	55) (316,877,677)	(146,400,125)	(129,096,357)
Income Tax Paid (239,022,5 Net Cash From Operating Activities State of Property, Plant and Equipment Investment in Mature Biological Assets Acquisition of Right to Use Asset Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4		·	(152,000)
Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4			- (132)666)
Net Cash From (Used In) Investing Activities Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4		(42
Acquisition of Property, Plant and Equipment (794,499,4 Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	52 536,762,824	(187,407,664)	(91,104,679)
Investment in Mature Biological Assets (21,925,8 Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	(011 401 700)	(20, 400, 222)	(24 225 045)
Acquisition of Right to Use Asset (9,706,0 Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4		(20,480,333)	(21,225,915)
Proceeds from sale of Property, Plant and Equipment 13,500,0 Investment in New Projects 9,218,4	•	(9,706,044)	
		13,500,000	1,000,000
I and a second of the first of I A and	98 (1,524,245)	9,218,498	(1,524,245)
Investment on Other Financial Assets -	(31,841,500)		(31,841,500)
Finance Income Received 1,124,2	2,614,759	1,133,501	2,218,401
Investment in Subsidiaries - Investment in Joint Ventures -	(27,246,116)	-	(367,728,672)
Dividend Received 40,368,7		217,213,930	257,980,250
Net Cash Flow Used in Investing Activities (761,919,7			(188,367,796)
Cash From (Used in) Financing Activities			
Proceeds from Subscription to ESOS Shares 51,931,3	33	51,931,383	
Dividend Payments (91,749,5			(104,723,183)
Principal Payment under Ijara-Leases (Motor Vehicle) (7,010,5	(5,144,838)	(5,534,960)	(4,004,604)
Principal Payment under Diminishing Musharakah Facilities (661,023,5			(50,000,000)
Principal Payment under Wakala -	(7,000,000)		- (4.224.475)
Principal Payment under SLFRS 16 - Non- Motor (17,152,6			(1,221,475)
Principal Payment Short Term Facilities (331,980,5 Proceeds from Wakala Facilities	(104,714,453) 5,000,000	(331,980,588)	(104,714,453)
Proceeds from Ijara-Leases (Motor Vehicle) 5,500,0		5,500,000	
Proceeds from Diminishing Musharakah Facilities 962,487,8	2,026,500	177,391,087	<u> </u>
Proceeds from Short Term Facilities 366,808,0		366,808,055	522,833,126
Net Cash From (Used In) Financing Activities 277,810,3	713,457,782	75,196,446	258,169,411
Net Increase/(Decrease) in Cash & Cash Equivalents 48,592,6	713,457,782 55 522,833,126		
Cash & Cash Equivalents at the beginning of period 366,223,8	713,457,782 55 522,833,126 505,825,039 11 125,913,096	98,668,334	
Cash & Cash Equivalents at end of period 414,816,4	713,457,782 55 522,833,126 505,825,039 11 125,913,096 240,310,787	7,637,282	(21,303,065) 28,940,347
Movement in cash and cash equivalents	713,457,782 55 522,833,126 505,825,039 11 125,913,096 240,310,787		
Components of Cash and Cash Equivalents 362,5 Cash and Bank Balances 414,453,9	713,457,782 55 522,833,126 505,825,039 11 125,913,096 240,310,787 366,223,883	7,637,282 106,305,616	28,940,347 7,637,282
Cash and Bank Balances 414,453,9 At the end of the period 414,816,4	713,457,782 55 522,833,126 505,825,039 11 125,913,096 240,310,787 366,223,883 00 362,500	7,637,282	28,940,347

^{*} The amounts are provisional and subject to audit

NOTES TO THE FINANCIAL STATEMENTS

- 1. The condensed interim financial statements have been prepared in accordance with Sri Lanka Accounting Standards LKAS 34 on Interim Financial Reporting. The condensed interim financial statements should be read in conjunction with the annual financial statements for the year ended 31st March 2020 including the changes to accounting policies, as a result of convergence to the revised Sri Lanka Accounting Standards ('SLFRSs/LKASs'). Further, the provisions of the Companies Act No 7 of 2007 have been considered in preparing the interim financial statements. The figures in the presented financial statements are provisional and subject to audit unless otherwise stated.
- 2. The summarized financial information of the Joint Ventures and the Associates, which are now being accounted under Equity method, is presented below:

Investment in Joint Ventures & Associate	As At	As At
	31/03/2021	31/03/2020
Gurugoda Hydro (Pvt) Ltd	53,914,055	52,435,870
Vidul Madugeta (Pvt) Ltd	252,744,263	226,065,394
Nilwala Vidulibala Company (Pvt) Ltd	115,148,552	96,695,538
Vidul Biomass (Pvt) Ltd	219,258,179	197,798,032
Total investment in Joint Ventures	641,065,048	572,994,834
Share of comprehensive income from the Joint Ventures	Year Ended	Year Ended
& Associate	31/03/2021	31/03/2020
Gurugoda Hydro (Pvt) Ltd	1,478,185	(1,450,053)
Vidul Madugeta (Pvt) Ltd	51,428,869	45,887,845
Nilwala Vidulibala Company (Pvt) Ltd	34,071,764	24,528,618
Vidul Biomass (Pvt) Ltd	21,460,147	(38,590,886)
Total share of comprehensive income from Joint Ventures	108,438,964	30,375,524

3. Operating Segment Information.

For the Year Ended 31/03/2021	Power Generation Hydro-Local	Power Generation Hydro- Overseas	Power Generation- Dendro & Plantation - Local	Engineering Consultancy & Project Manageme nt	Total
Revenue	769,595,777	798,568,199	194,669,168	34,301,004	1,797,134,148
Gross Profit	587,478,279	581,807,092	1,084,258	32,628,133	1,202,997,762
Profit After Tax	219,060,574	379,312,981	3,981,335	(1,321,601)	601,033,289
Total Assets	3,671,076,650	4,382,812,952	137,899,704	171,434,973	8,363,224,279
Total Liabilities	1,800,468,050	2,625,471,469	135,288,644	153,481,820	4,714,709,982

For the Year Ended 31/03/2020	Power Generation Hydro-Local	Power Generation Hydro- Overseas	Power Generation- Dendro & Plantation - Local	Engineering Consultancy & Project Manageme nt	Total
Revenue	729,158,458	593,430,549	97,809,521	19,981,935	1,440,380,462
Gross Profit	211,862,963	432,728,782	(51,624,066)	-10,869,133	1,062,482,748
Profit After Tax	137,183,068	299,229,964	(51,624,066)	(23,127,134)	361,661,833
Total Assets	3,469,943,364	3,583,818,177	127,176,611	201,549,660	7,382,487,812
Total Liabilities	1,793,066,850	2,291,873,822	107,086,738	189,663,508	4,381,690,918

- 4. There has not been any significant change in contingent liabilities, which were disclosed in the Annual Report for the financial year ended 31st March 2020.
- 5. No circumstance has arisen since the Balance Sheet date, which would require adjustments to or disclosure in the financial statements, other than the disclosures made in this interim financial statement.
- 6. Presently the group is receiving generation payments from Ceylon Electricity Board in arrears from 90 days to 120 days, as opposed to 30 days stipulated in the power purchasing agreements and the company is actively engaged with CEB and the authorities to regularize of the dues. The group has obtained working capital facilities including "Saubaghya Covid 19 Renaissance Facility" program.
- 7. Group Income Tax expenses includes Rs. 83.69 Mn of Deferred Tax provision and Rs 11.16 Mn Dividend tax.
- 8. Company paid an interim dividend of Rs .10 Cents per share on 21st December 2020 and amounting to a total distribution of Rs. 84.19 Mn paid on 25th January 2021.
- 9. Company announced a rights issues of non-voting share at a ratio of 1 non-voting share for every 11.72 ordinary voting shares held and this is for the purpose of investments in rooftop and ground mounted solar projects.
- 10. A total of 10,673,224 ordinary voting shares were issued during the financial year consequent to the subscription to the share options under the employee share option scheme, of which 2,643,921 shares issued during March 2021 were listed on 2nd April 2021.
- 11. Market price per share during the quarter end.

	31st March 2021		31st March 2020	
Description	Date	Rs.	Date	Rs.
Market Price-Highest	25/01/2021	6.00	17/02/2020	5.00
Market Price-Lowest	11/02/2021	5.00	20/03/2020	4.10
Market Price-last Traded	31/03/2021	5.50	20/03/2020	4.10

12. Directors' Shareholding as of 31st March 2021.

	Name of Director / CEO	No of Shares
1	Mr. Osman Kassim	19,000,000
2	Mr. Osman Kassim / Ms K Kassim	104,115,292
3	Mr. Riyaz M. Sangani	131,406,138
4	Mr. Sattar Kassim	101,135,861
5	Mr. Sujendra Mather	20,626,246
6	Mr. Ranjan Mather	119,000,000
7	Mr. Sidath Fernando	5,180,000
8	Mr. Shahid M. Sangani	9,365,488
9	Mr. C.F Fuhrer	1,098,398
10	Ms. Deepthie Wickramasuriya	Nil
11	Mr. Rizvi Zaheed	Nil

13. The top 20 shareholders as of 31st March 2021.

	Name	Shares	%
1	Mr. Riyaz M. Sangani	131,406,138	15.49%
2	Mr. Ranjan Mather	119,000,000	14.03%
3	Wembley Spirit Limited	108,943,372	12.84%
4	Mr. Osman Kassim /Mrs K Kassim	104,115,292	12.27%
5	Mr. Sattar Kassim	101,135,861	11.92%
6	Ms. R.L. Mather	46,925,007	5.53%
7	Mrs. Yumna Kunimoto	25,275,451	2.98%
8	ABC International Ltd	24,860,175	2.93%
9	Mr. Mohamed Shafee Mohideen	21,172,720	2.50%
10	Mr. Sujendra Mather	20,626,246	2.43%
11	Mr. Osman Kassim	19,000,000	2.24%
12	Dynawash Ltd	17,966,598	2.12%
13	Mr. Ranjeet Bhanwarlal Barmecha	11,880,003	1.40%
14	Mr. Shahid M. Sangani	9,365,488	1.10%
15	Ms. D.Z. Kathawala	8,839,461	1.04%
16	Vanguard Industries (Pvt) Ltd	7,606,012	0.90%
17	Jaywise Construction Ltd	5,917,099	0.70%
18	Mr. Sidath Fernando	5,180,000	0.61%
19	Ms. S.S.Sangani	2,744,955	0.32%
20	Mr. F K. Mohideen	2,017,913	0.24%
		793,977,791	93.58%

14. Public Shareholding information as of 31^{st} March 2021.

Issued number of shares	848,458,689
Public Shareholding	178,374,898
Public Holding - %	21.02%
Public Holding - No of Shareholders	2412
Non Public Shareholding	670,083,791
Non Public Shareholding %	78.98%
Non Public Holding - No of Shareholders	16
Existing Floated adjusted Market Capitalization	981,061,939
Option for Compliance - Option 5 of 7.13.1 (a) of the Listing Rules	

CORPORATE INFORMATION

COMPANY STATUS

Public Limited Liability Company Listed in the Colombo Stock Exchange on 10th June 2005

RE-REGISTRATION DATE & NUMBER

27th September 2007 PQ 83

COMPANY SECRETARY

Managers & Secretaries (Pvt) Ltd No 8, Tickle Road Colombo 08

STATED CAPITAL

Rs. 1,469,839,867/-

ISSUED NUMBER OF SHARES

848,458,689 Shares

REGISTERED OFFICE

Level 04, Access Towers
No 278 Union Place
Colombo 02
Telephone – 011 4760000
Fax – 011 4760076
Email – info@vidullanka.com
Web – www.vidullanka.com

AUDITORS

M/s. Ernst & Young, Chartered Accountants No 201, De Saram Place Colombo 10

BANKERS

Amana Bank PLC
Hatton National Bank PLC
Commercial Bank of Ceylon PLC
Bank of Ceylon
NDB Bank PLC
Stanbic Bank Uganda Limited
Seylan Bank PLC
MCB Bank Limited

WEBSITE

www.vidullanka.com